Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311615226> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W4311615226 abstract "Abstract Background Adintrevimab is a fully human IgG1 monoclonal antibody engineered to have potent and broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other SARS-like CoVs with pandemic potential. Adintrevimab is being assessed in two separate phase 2/3 clinical trials: the EVADE trial for prevention of COVID-19 in both post-exposure and pre-exposure settings and the STAMP trial for treatment of COVID-19. Here we report higher doses being evaluated in a healthy volunteer study given that emerging variants may have varying susceptibilities to adintrevimab. Previous results 300 mg IM, 600 mg IM, and 500 mg IV cohorts have been reported. Methods This is an ongoing Phase 1, randomized, placebo (PBO)-controlled, single ascending-dose study of adintrevimab administered intramuscularly (IM) or intravenously (IV) to healthy adults aged 18–50 years with no current SARS-CoV-2 infection. Participants were randomized 8:2 in 3 high dose cohorts (N=10/cohort: n=8 adintrevimab, n=2 PBO): adintrevimab 1200 mg IM, 1200 mg IV, and 4500 mg IV. Safety, tolerability, and pharmacokinetics (PK) were assessed up to 21 days post dose. Results Overall, 30 participants received adintrevimab (n=24) or PBO (n=6). Blinded safety data for all cohorts and PK for 1200 mg IV are reported. Through 21 days post dose all doses were well-tolerated, with no study drug-related adverse events (AEs), serious AEs, injection site reactions, or hypersensitivity reactions reported. The observed PK profile of the 1200 mg IV dose included Cmax of 423±105 µg/ml. Comparison of 500 mg and 1200 mg IV doses indicate dose proportionality of Cmax and exposure (AUC Day 21). Conclusion A single dose of adintrevimab, up to 4500 mg, was well tolerated. These preliminary safety data and PK support potential use of higher doses of adintrevimab as needed to address emerging SARS-CoV-2 variants. Disclosures Xia Pu, PhD, Adagio Therapeutics: Employee|Adagio Therapeutics: Stocks/Bonds Jean Gong, PhD, Adagio Therapeutics: Employee|Adagio Therapeutics: Stocks/Bonds Ed Campanaro, BSN, MSHS, Adagio Therapeutics: Employee|Adagio Therapeutics: Stocks/Bonds Kristin Narayan, PhD, Adagio Therapeutics: Employee|Adagio Therapeutics: Stocks/Bonds Deepali Gupta, B.Sc, Adagio Therapeutics: Employee|Adagio Therapeutics: Stocks/Bonds Frank Engler, PhD, Adagio Therapeutics: Advisor/Consultant Amanda Copans, PharmD, Adagio Therapeutics: Employee|Adagio Therapeutics: Stocks/Bonds Pete Schmidt, MD, Adagio Therapeutics: Employee|Adagio Therapeutics: Stocks/Bonds." @default.
- W4311615226 created "2022-12-27" @default.
- W4311615226 creator A5019207632 @default.
- W4311615226 creator A5039024909 @default.
- W4311615226 creator A5041600708 @default.
- W4311615226 creator A5044627377 @default.
- W4311615226 creator A5046144485 @default.
- W4311615226 creator A5053336305 @default.
- W4311615226 creator A5055408047 @default.
- W4311615226 creator A5081757083 @default.
- W4311615226 date "2022-12-01" @default.
- W4311615226 modified "2023-10-18" @default.
- W4311615226 title "226. Higher Doses of Adintrevimab, an Extended Half-Life Monoclonal Antibody, for the Treatment and Prevention of COVID-19: Preliminary Results from a Phase 1 Single Ascending-Dose Study" @default.
- W4311615226 doi "https://doi.org/10.1093/ofid/ofac492.304" @default.
- W4311615226 hasPublicationYear "2022" @default.
- W4311615226 type Work @default.
- W4311615226 citedByCount "0" @default.
- W4311615226 crossrefType "journal-article" @default.
- W4311615226 hasAuthorship W4311615226A5019207632 @default.
- W4311615226 hasAuthorship W4311615226A5039024909 @default.
- W4311615226 hasAuthorship W4311615226A5041600708 @default.
- W4311615226 hasAuthorship W4311615226A5044627377 @default.
- W4311615226 hasAuthorship W4311615226A5046144485 @default.
- W4311615226 hasAuthorship W4311615226A5053336305 @default.
- W4311615226 hasAuthorship W4311615226A5055408047 @default.
- W4311615226 hasAuthorship W4311615226A5081757083 @default.
- W4311615226 hasBestOaLocation W43116152261 @default.
- W4311615226 hasConcept C112705442 @default.
- W4311615226 hasConcept C126322002 @default.
- W4311615226 hasConcept C142724271 @default.
- W4311615226 hasConcept C168563851 @default.
- W4311615226 hasConcept C197934379 @default.
- W4311615226 hasConcept C204787440 @default.
- W4311615226 hasConcept C22979827 @default.
- W4311615226 hasConcept C27081682 @default.
- W4311615226 hasConcept C2776768635 @default.
- W4311615226 hasConcept C2777288759 @default.
- W4311615226 hasConcept C2778375690 @default.
- W4311615226 hasConcept C2779134260 @default.
- W4311615226 hasConcept C3008058167 @default.
- W4311615226 hasConcept C524204448 @default.
- W4311615226 hasConcept C535046627 @default.
- W4311615226 hasConcept C6557445 @default.
- W4311615226 hasConcept C71924100 @default.
- W4311615226 hasConcept C86803240 @default.
- W4311615226 hasConcept C98274493 @default.
- W4311615226 hasConceptScore W4311615226C112705442 @default.
- W4311615226 hasConceptScore W4311615226C126322002 @default.
- W4311615226 hasConceptScore W4311615226C142724271 @default.
- W4311615226 hasConceptScore W4311615226C168563851 @default.
- W4311615226 hasConceptScore W4311615226C197934379 @default.
- W4311615226 hasConceptScore W4311615226C204787440 @default.
- W4311615226 hasConceptScore W4311615226C22979827 @default.
- W4311615226 hasConceptScore W4311615226C27081682 @default.
- W4311615226 hasConceptScore W4311615226C2776768635 @default.
- W4311615226 hasConceptScore W4311615226C2777288759 @default.
- W4311615226 hasConceptScore W4311615226C2778375690 @default.
- W4311615226 hasConceptScore W4311615226C2779134260 @default.
- W4311615226 hasConceptScore W4311615226C3008058167 @default.
- W4311615226 hasConceptScore W4311615226C524204448 @default.
- W4311615226 hasConceptScore W4311615226C535046627 @default.
- W4311615226 hasConceptScore W4311615226C6557445 @default.
- W4311615226 hasConceptScore W4311615226C71924100 @default.
- W4311615226 hasConceptScore W4311615226C86803240 @default.
- W4311615226 hasConceptScore W4311615226C98274493 @default.
- W4311615226 hasIssue "Supplement_2" @default.
- W4311615226 hasLocation W43116152261 @default.
- W4311615226 hasOpenAccess W4311615226 @default.
- W4311615226 hasPrimaryLocation W43116152261 @default.
- W4311615226 hasRelatedWork W2051764329 @default.
- W4311615226 hasRelatedWork W2064759457 @default.
- W4311615226 hasRelatedWork W2074207917 @default.
- W4311615226 hasRelatedWork W2094883508 @default.
- W4311615226 hasRelatedWork W2319060667 @default.
- W4311615226 hasRelatedWork W2903024464 @default.
- W4311615226 hasRelatedWork W3087516196 @default.
- W4311615226 hasRelatedWork W3151787567 @default.
- W4311615226 hasRelatedWork W3178697376 @default.
- W4311615226 hasRelatedWork W4308071420 @default.
- W4311615226 hasVolume "9" @default.
- W4311615226 isParatext "false" @default.
- W4311615226 isRetracted "false" @default.
- W4311615226 workType "article" @default.